Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
1248979
Reference Type
Journal Article
Title
Curcumin encapsulated in chitosan nanoparticles: A novel strategy for the treatment of arsenic toxicity
Author(s)
Yadav, A; Lomash, V; Samim, M; Flora, SJS
Year
2012
Is Peer Reviewed?
Yes
Journal
Chemico-Biological Interactions
ISSN:
0009-2797
EISSN:
1872-7786
Volume
199
Issue
1
Page Numbers
49-61
Language
English
PMID
22704994
DOI
10.1016/j.cbi.2012.05.011
Web of Science Id
WOS:000307419600006
Abstract
Water-soluble nanoparticles of curcumin were synthesized, characterized and applied as a stable detoxifying agent for arsenic poisoning. Chitosan nanoparticles of less than 50nm in diameter containing curcumin were prepared. The particles were characterized by TEM, DLS and FT-IR. The therapeutic efficacy of the encapsulated curcumin nanoparticles (ECNPs) against arsenic-induced toxicity in rats was investigated. Sodium arsenite (2mg/kg) and ECNPs (1.5 or 15mg/kg) were orally administered to male Wistar rats for 4weeks to evaluate the therapeutic potential of ECNPs in blood and soft tissues. Arsenic significantly decreased blood δ-aminolevulinic acid dehydratase (δ-ALAD) activity, reduced glutathione (GSH) and increased blood reactive oxygen species (ROS). These changes were accompanied by increases in hepatic total ROS, oxidized glutathione, and thiobarbituric acid-reactive substance levels. By contrast, hepatic GSH, superoxide dismutase and catalase activities significantly decreased on arsenic exposure, indicative of oxidative stress. Brain biogenic amines (dopamine, norepinephrine and 5-hydroxytryptamine) levels also showed significant changes on arsenic exposure. Co-administration of ECNPs provided pronounced beneficial effects on the adverse changes in oxidative stress parameters induced by arsenic. The results indicate that ECNPs have better antioxidant and chelating potential (even at the lower dose of 1.5mg/kg) compared to free curcumin at 15mg/kg. The significant neurochemical and immunohistochemical protection afforded by ECNPs indicates their neuroprotective efficacy. The formulation provides a novel therapeutic regime for preventing arsenic toxicity.
Keywords
Nanoencapsulation; Curcumin; Arsenic; Oxidative stress; Preventive therapy
Tags
•
Arsenic Hazard ID
1. Initial Lit Search
PubMed
WOS
ToxNet
WOS
Considered New
2. Lit Search Updates through Oct 2015
WOS
Considered
4. Considered through Oct 2015
6. Cluster Filter through Oct 2015
7. Other Studies through Oct 2015
MOA
iAs MOA Literature Categorization
Cytotoxicity and Regenerative Proliferation
Epigenetic Mechanisms
Immune
•
Arsenic (Inorganic)
1. Literature
PubMed
Toxline, TSCATS, & DART
Web of Science
Lit search updates through Oct 2015
3. Hazard ID Screening
Other potentially supporting studies
4. Adverse Outcome Pathways/Networks Screening
Relevant
•
Arsenic MOA
4. Adverse Outcome Pathways
Oxidative stress related effects (includes non-specific SH reactions)
5. Health Effect
Hematology, Hematopoietic System
Liver Effects
Nervous System Effects
1. MOA Literature Screening
Health Effect Screening
MOA Cluster
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity